Follow-up study of a nation-wide neonatal metabolic screening program in Japan

• DOI: 10.1007/bf00442450
• Publication Date: 2004-11-12T04:05:15Z
• Authors: K. Tada; H. Tateda; S. Arashima; K. Sakai; T. Kitagawa; K. Aoki; S. Suwa; M. Kawamura; T. Oura; M. Takesada; Y. Kuroda; F. Yamashita; I. Matsuda; H. Naruse
• Keywords: Galactosemias; Male; 0301 basic medicine; Phenylalanine; Intelligence; Infant, Newborn; Infant; 3. Good health; Biopterins; 03 medical and health sciences; 0302 clinical medicine; Japan; Maple Syrup Urine Disease; Phenylketonurias; Humans; Mass Screening; Female; Histidine; Homocystinuria; Metabolism, Inborn Errors; Follow-Up Studies

A nationwide neonatal screening program for phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, histidinemia and galactosemia was started in Japan in 1977. The total number of infants screened had reached 6,311,754 by March, 1982. A follow-up study revealed the incidence of the disease in Japan: 1/108,823 for PKU; 1/450,840 for hyperphenylalaninemia (HPA); 1/1,577,939 for biopterin deficiency; 1/525,980 for MSUD; 1/1,051,959 for homocystinuria; 1/8,371 for histidinemia, and 1/788,969 for galactosemia type 1. The incidences of PKU, HPA, homocystinuria, and galactosemia (type 1) were found to be markedly low in Japan as compared with those in Caucasian countries. There was no great difference in the incidence of MSUD between both. On the other hand, the incidence of histidinemia was higher in Japan. It was found that most of the patients with PKU, HPA, MSUD, homocystinuria, or galactosemia are developing normally due to the early initiation of dietary treatment. These results clearly indicate that the neonatal mass screening program plays a great role in preventing the occurrence of handicapped children.